Omkar Speciality Chemicals Limited (OMKARCHEM)
Snapshot
Events
- Latest results
- Q4 FY26
- Board meeting filing
- 14 Aug 2026
Exchange data. Each figure as its own page shows it; the dates are the data's. Information only, not investment advice.
📈 Share price & events
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Omkar Speciality's revenue was ₹0.0 Cr, and net profit ₹-0.3 Cr; the operating margin was -1800.0%.
| Q4 FY26 (₹ Cr) | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹0.0 | — | — |
| Operating profit | ₹-0.2 | — | loss widened |
| Net profit | ₹-0.3 | — | — |
| EPS (₹) | -0.16 | — | — |
| Operating margin | -1800.0% | — | — |
📢 Recent Corporate Announcements
Omkar Speciality Chemicals issued a corrigendum clarifying the plot sizes for its previously approved asset sale in MIDC Industrial Area, Badlapur, District Thane, Maharashtra. The correct plot areas comprise Plot No. F-09 measuring 2,519 Sq. Mtrs. and Plot No. F-10 measuring 7,135 Sq. Mtrs., totalling 9,654 Sq. Mtrs. The transaction details, including commercial consideration and buyer information, were not disclosed in this specific filing. All other terms from the board approval dated October 19, 2026, remain unchanged.
- Corrigendum clarifies area for two MIDC Industrial Area plots in Badlapur, Thane
- Plot No. F-09 correctly specified as admeasuring 2,519 Sq. Mtrs.
- Plot No. F-10 correctly specified as admeasuring 7,135 Sq. Mtrs.
- Total land area involved in the proposed sale is 9,654 Sq. Mtrs.
- Sale was originally approved by the Board of Directors on October 19, 2026
Omkar Speciality Chemicals has approved the sale of two industrial land plots situated at MIDC Industrial Area, Badlapur, District Thane. The properties include Plot No. F-09 (2,519 sq. mtrs.) and Plot No. F-10 (5,874 sq. mtrs.), totaling 8,393 sq. mtrs. Financial terms, including sale consideration and buyer details, were not disclosed in the filing. The company stated it will make further disclosures as sale transactions progress.
- Board approved the sale of Plot No. F-09 admeasuring 2519 Sq. Mtrs.
- Board approved the sale of Plot No. F-10 admeasuring 5874 Sq. Mtrs.
- Total property area approved for sale stands at 8,393 Sq. Mtrs.
- Sale consideration and transaction values were not disclosed
Omkar Speciality Chemicals has approved the appointment of Ms. Shashi Kala Dhabriya as an Additional Non-Executive Independent Director for a 5-year term from October 15, 2026, to October 14, 2031, subject to shareholder approval. Concurrently, Ms. Muskaan Pherwani resigned from her position as an Additional Non-Executive Independent Director effective October 13, 2026, citing personal and professional commitments. The outgoing director noted challenges allocating time to a company undergoing restructuring and growth. These changes are administrative board alterations and do not directly impact current operational or financial metrics.
- Appointment of Ms. Shashi Kala Dhabriya as Independent Director for a 5-year tenure effective October 15, 2026
- Resignation of Ms. Muskaan Pherwani as Independent Director effective close of business hours on October 13, 2026
- Board meeting commenced at 04:00 p.m. and concluded at 06:00 p.m. on October 15, 2026
Omkar Speciality Chemicals has submitted a clarification to the stock exchange regarding its audited financial results for the financial year ended March 31, 2026. The submission addresses exchange queries by providing machine-readable formats and an auditor declaration under Regulation 33(3)(d) confirming an unmodified audit opinion from statutory auditor R.R. Tibrewala & Co. The audit report notes the implementation of the NCLT-approved Resolution Plan submitted by Kshitij Polyline Limited (approved on July 31, 2025) involving significant restatements of assets, liabilities, and equity.
- Auditor R.R. Tibrewala & Co. issued an unmodified opinion on FY26 financial statements
- Resolution Plan by Kshitij Polyline Limited approved by NCLT Mumbai on July 31, 2025 was implemented in FY26
- Board approved constitution of Nomination and Remuneration Committee headed by Independent Director Mr. Bhupeshkumar Jain
- Exchange procedural queries resolved through revised legible submission and regulatory declarations on August 7, 2026
Omkar Speciality Chemicals reported zero revenue from operations for the quarter ended June 30, 2026, identical to the nil revenue in the corresponding quarter of the previous year. The company posted a net loss of Rs 36.07 Lakhs for the quarter, marginally narrower than the Rs 40.98 Lakhs loss in Q1 FY26. Total expenses stood at Rs 36.07 Lakhs, consisting mainly of depreciation (Rs 21.73 Lakhs) and other expenses (Rs 13.50 Lakhs). Statutory auditors highlighted the ongoing implementation of the NCLT-approved Resolution Plan dated July 31, 2025, noting that lender dues have been settled as the company prepares to restart commercial operations.
- Revenue from operations was Nil for Q1 FY27, compared to Nil in Q1 FY26 and Rs 0.82 Lakhs in Q4 FY26.
- Net loss stood at Rs 36.07 Lakhs versus a net loss of Rs 40.98 Lakhs in the year-ago quarter.
- Total expenses of Rs 36.07 Lakhs were dominated by Rs 21.73 Lakhs in depreciation and Rs 13.50 Lakhs in other administrative expenses.
- Auditor emphasis of matter noted the implementation of the NCLT Resolution Plan (dated July 31, 2025) and repayment of financial creditors.
Omkar Speciality Chemicals has officially implemented its NCLT-approved resolution plan with Kshitij Polyline Limited as the successful applicant. For FY26, the company reported a net loss of ₹1.58 crore on negligible revenue of ₹0.82 lakhs, as manufacturing operations remain suspended. The resolution applicant has infused ₹23.42 crore into the company as of March 31, 2026, to facilitate revival and debt settlement. Despite negative other equity of ₹1.85 crore, the management is proceeding on a 'going concern' basis following the equity restructuring and fund infusion.
- Net loss of ₹158.88 Lakhs for FY26, widening from a loss of ₹130.37 Lakhs in the previous year
- Total fund infusion of ₹2,342.13 Lakhs by the Resolution Applicant (Kshitij Polyline) as of March 31, 2026
- Revenue from operations was nearly non-existent at ₹0.82 Lakhs for the full year due to suspended manufacturing
- Paid-up equity share capital restructured to ₹2,057.80 Lakhs following the extinguishment and reissuance of shares
- Resolution plan implementation resulted in significant restatement of borrowings, trade payables, and provisions
Omkar Speciality Chemicals has scheduled a board meeting for August 7, 2026, to approve a multi-year backlog of financial results covering FY23, FY24, and FY25. The company was previously under the Corporate Insolvency Resolution Process (CIRP), which caused the suspension of trading and non-submission of results since FY22. This is a critical regulatory step toward potentially resuming trading on the BSE and NSE. Investors should remain cautious as the company's current financial health post-insolvency remains unquantified until these reports are released.
- Board meeting scheduled for August 7, 2026, to approve results for three consecutive fiscal years (FY23, FY24, FY25).
- Backlog includes quarterly results starting from September 2022 through March 2025.
- Company was under Corporate Insolvency Resolution Process (CIRP) under the IBC 2016, leading to operational constraints.
- Trading in equity shares remains suspended on both BSE and NSE as of the announcement date.
- Promoter holding stands at a high 95.0%, indicating very limited public float.
The Board of Directors of Omkar Speciality Chemicals has approved the sale of two industrial properties in the MIDC Industrial Area, Badlapur. The assets include Plot No. W 83 (880 Sq. Mtrs.) and Plot No. W 93 (720 Sq. Mtrs.). This move appears to be part of an asset monetization or restructuring strategy, as the company's contact details suggest involvement in a Corporate Insolvency Resolution Process (CIRP). Investors should monitor the final sale value and how the proceeds are utilized for debt settlement.
- Approval for sale of Plot No. W 83 measuring 880 Sq. Mtrs. in MIDC Badlapur.
- Approval for sale of Plot No. W 93 measuring 720 Sq. Mtrs. in MIDC Badlapur.
- The decision was finalized in a Board Meeting held on June 25, 2026.
- Company contact information indicates ongoing CIRP (Insolvency) proceedings.
Omkar Speciality Chemicals Limited has released its financial results for the year ended March 31, 2026, following the implementation of an NCLT-approved Resolution Plan dated July 31, 2025. The auditors have issued an unmodified opinion but included an 'Emphasis of Matter' regarding the company's status as a 'Going Concern' and the significant restatement of assets and liabilities. The company reported a loss for the year, and the resolution process involved the extinguishment and reissuance of equity shares. Additionally, the company has failed to transfer ₹1.21 Lakhs in unclaimed dividends to the IEPF.
- NCLT approved the Resolution Plan on July 31, 2025, resulting in significant restatement of borrowings, trade payables, and equity.
- Auditors highlighted a 'Going Concern' uncertainty despite the implementation of the restructuring plan.
- The company failed to transfer ₹1.21 Lakhs of unpaid/unclaimed dividends from FY 2014-15 and FY 2015-16 to the Investor Education and Protection Fund (IEPF).
- The financial statements for the previous year (FY25) were audited by a different firm, Satya Prakash Natani & Co.
- Implementation of the plan included the infusion of funds by the Resolution Applicant and the restatement of certain assets.
Omkar Speciality Chemicals has appointed M/s. Aabid & Co as Secretarial Auditor for FY 2025-26 following a board meeting on May 27, 2026. The company released delayed limited review reports for the first three quarters of FY 2025-26, noting that a Resolution Plan was approved by the NCLT on July 31, 2025. However, auditors have issued qualified conclusions due to the company's negative net worth and continued losses. Notably, comparative financial figures for FY 2024-25 are unavailable as the company failed to prepare results during its insolvency period.
- NCLT approved a Resolution Plan for the company on July 31, 2025, ending the CIRP phase.
- Auditors issued qualified conclusions for Q1, Q2, and Q3 of FY 2025-26 due to negative net worth.
- Financial results for the first three quarters of FY 2024-25 were not prepared, leaving no comparative data.
- M/s. Aabid & Co, Company Secretaries, appointed as Secretarial Auditor for the financial year 2025-26.
- The company continues to report losses, indicating material uncertainty regarding its status as a going concern.
Omkar Speciality Chemicals has appointed Mr. Dipak Kumar Shaw as the new CEO following a board meeting on May 27, 2026. The company recently emerged from the Corporate Insolvency Resolution Process (CIRP) with a resolution plan approved by the NCLT on July 31, 2025. However, the company continues to report losses and maintains a negative net worth, leading to a qualified opinion from auditors for the first three quarters of FY 2025-26. Financial results for the previous year (FY 2024-25) were not prepared, leaving investors without comparative performance data.
- Appointment of Mr. Dipak Kumar Shaw as Chief Executive Officer (CEO) effective May 27, 2026.
- Hon’ble NCLT approved the Resolution Plan for the company on July 31, 2025, ending the CIRP period.
- Auditors issued a qualified conclusion for Q1, Q2, and Q3 of FY 2025-26 due to negative net worth and material uncertainty.
- Comparative quarterly figures for FY 2024-25 are unavailable as results were not prepared during the insolvency process.
- Financial results are currently being prepared on a 'going concern' basis following the resolution plan approval.
Omkar Speciality Chemicals has released financial results for the quarters ending June, September, and December 2025 following the NCLT's approval of its Resolution Plan on July 31, 2025. The auditors have issued a qualified opinion, highlighting that the company has a negative net worth and continues to incur losses, which creates material uncertainty regarding its status as a going concern. Additionally, comparative figures for the previous financial year (2024-25) are unavailable because the company did not prepare results while under the Corporate Insolvency Resolution Process (CIRP). While the approved plan provides a framework for recovery, the current financial position remains highly distressed.
- NCLT approved the company's Resolution Plan on July 31, 2025, ending the CIRP phase.
- Auditors issued a qualified conclusion due to negative net worth and persistent losses during the reviewed periods.
- Comparative financial data for the first three quarters of FY 2024-25 is missing as results were not prepared.
- Financial statements for June, September, and December 2025 were all signed off on May 27, 2026.
- Results were prepared on a going concern basis solely due to the subsequent approval of the resolution plan.
Omkar Speciality Chemicals has released its delayed financial results for the first three quarters of FY 2025-26, revealing continued losses and a negative net worth. The company was under the Corporate Insolvency Resolution Process (CIRP) during the period, with a Resolution Plan finally approved by the NCLT on July 31, 2025. Auditors have issued a qualified opinion due to the lack of comparative figures from the previous year and significant uncertainty regarding the company's ability to continue as a going concern. These results were finalized significantly late, in May 2026, reflecting the administrative challenges during the insolvency process.
- Resolution Plan approved by Hon’ble NCLT on July 31, 2025, providing a potential path for recovery.
- Auditors issued a qualified conclusion citing negative net worth and material uncertainty over going concern status.
- No comparative quarterly figures available for FY 2024-25 as the company failed to prepare results for those periods.
- Company reported persistent losses across the quarters ended June, September, and December 2025.
- Financial results for all three quarters were delayed and only signed off by auditors on May 27, 2026.
Omkar Speciality Chemicals, currently under the Corporate Insolvency Resolution Process (CIRP), has scheduled a Monitoring Committee meeting for May 27, 2026. The committee will review and approve pending financial results for the quarters ended June, September, and December 2025. Key leadership appointments are on the agenda, including a new CEO and an Independent Director, alongside the reconstitution of essential board committees. This meeting marks a critical step in regularizing governance and financial reporting following the company's admission into CIRP in December 2022.
- Approval of unaudited financial statements for three consecutive quarters of 2025 (June, Sept, Dec).
- Appointment of Mr. Dipak Kumar Shaw as the Chief Executive Officer (CEO) of the company.
- Appointment of Mr. Ruhini Kumar Chakraborty as an Independent Director.
- Discussion regarding CIRP costs and the refund of Performance Bank Guarantees (PBG).
- Reconstitution of the Audit Committee and Stakeholder’s Relationship Committee.
Omkar Speciality Chemicals has announced a restructuring plan following its NCLT-approved resolution plan dated July 31, 2025. The plan involves reducing the entire existing share capital of the company to zero, effectively wiping out all current equity shareholders. Following this, fresh equity shares will be issued to the Resolution Applicant (RA) at a face value of INR 10, giving them 100% ownership. To meet SEBI's Minimum Public Shareholding requirements, the RA will later conduct an Offer for Sale (OFS) of 5% of the equity.
- Existing share capital to be reduced to NIL as per NCLT order dated July 31, 2025
- Resolution Applicant (RA) to be issued fresh equity shares at INR 10 face value
- RA will hold 100% of the company's paid-up capital post-allotment
- Company to conduct a 5% Offer for Sale (OFS) to achieve Minimum Public Shareholding
- The company has been under Corporate Insolvency Resolution Process (CIRP) since December 5, 2022
Company profilewritten 14 Dec 2025
Financial Performance
Revenue Growth by Segment
Total revenue grew 7% YoY to INR 86 Cr in Q1 FY18. The Pharmaceutical segment contributes 76% of revenue (down from 82-85% historically), while newly launched Fragrances and Food segments currently contribute 1-2% with a target to reach 10% as operations scale.
Geographic Revenue Split
Domestic sales account for approximately 80% of total revenue, while Exports contribute 20% across 38 countries including Europe, North America, China, and other Asian markets.
Profitability Margins
Gross margins for new products are targeted at 32-35%. Net profit grew 38% YoY to INR 7.6 Cr in Q1 FY18, driven by a shift toward higher-margin niche products and reduced interest costs.
EBITDA Margin
EBITDA margin stood at 17% in Q1 FY18, an improvement from approximately 15% in the previous year. Management targets a consistent EBITDA margin range of 17-18% based on optimized product mix and fungible manufacturing capacities.
Capital Expenditure
The company completed a major CAPEX cycle in FY17, increasing capacity by 800 MTPA. Future requirements are limited to maintenance CAPEX of approximately INR 4 Cr to 5 Cr per annum.
Credit Rating & Borrowing
The company is focused on debt reduction, repaying approximately INR 5 Cr to 6 Cr per quarter. High-cost debt has been largely repaid using proceeds from promoter stake sales to lower the overall interest burden.
Operational Drivers
Raw Materials
Not disclosed in available documents; however, the company utilizes specialized catalysts for its 200+ product portfolio.
Capacity Expansion
Current capacity was recently expanded by 800 MTPA through previous year's CAPEX. The company operates 5 manufacturing units and 1 R&D center to support its 200+ product range.
Raw Material Costs
Not disclosed as a specific percentage of revenue, but the company uses catalyst-driven processes to ensure higher yields and better customized products, which helps protect the 32-35% gross margin range.
Manufacturing Efficiency
The company employs in-house, multiproduct manufacturing facilities with catalyst-driven processes to ensure higher yields and customized product specifications.
Logistics & Distribution
The company exports to 38 countries; distribution is handled through a mix of direct supply to formulators and a network of distributors to manage credit risk.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
Growth will be achieved by diversifying the revenue base to reduce pharmaceutical dependence to 70%, scaling the newly launched Fragrance and Food segments to a 10% revenue share, and expanding export footprints in regulated markets. The company leverages its 17-18 patent filings and pioneer status in niche molecules to maintain high entry barriers.
Products & Services
Specialty chemicals including niche molecules for pharmaceuticals, glass, cosmetics, ceramics, cattle and poultry feeds, fragrances, flavors, and nutraceuticals.
Brand Portfolio
Omkar Speciality Chemicals; Lasa Supergenerics (demerged entity).
New Products/Services
Recently launched Fragrance and Food additives are expected to grow from 1-2% to 10% of total revenue contribution.
Market Expansion
Targeting increased export penetration beyond the current 20% share, focusing on 38 existing countries including North America and Europe.
Market Share & Ranking
Pioneer and one of the only manufacturers of many niche products in India; global market size for its new product segments is estimated at INR 500-600 Cr.
Strategic Alliances
The company underwent a demerger of its subsidiary, Lasa Supergenerics, which is now led independently by Omkar Herlekar to allow both entities to focus on specific growth opportunities.
External Factors
Industry Trends
The specialty chemicals industry is shifting toward high-quality customized products. While the pharma sector faces temporary regulatory headwinds, long-term demand remains robust due to population growth and lifestyle changes. Omkar is positioning itself by diversifying into FMCG and fragrance segments.
Competitive Landscape
Limited global competition in specific niche molecules; however, the company faces broader competition in the general pharmaceutical intermediate space.
Competitive Moat
The moat is sustained by pioneer status in niche products, patented catalyst-driven processes, and high entry barriers due to complex regulatory approval requirements. These factors protect the 17-18% EBITDA margins.
Macro Economic Sensitivity
The pharma sector is sensitive to US FDA regulatory changes, which impacts approximately 76% of the company's current business.
Consumer Behavior
Increased demand for nutraceuticals, fragrances, and food additives is driving the company's diversification strategy.
Geopolitical Risks
Trade barriers in regulated markets like Europe and North America could impact the 20% export revenue stream.
Regulatory & Governance
Industry Regulations
Operations are subject to US FDA regulatory standards for pharmaceutical clients and NCLT monitoring under the Insolvency and Bankruptcy Code (IBC) 2016.
Legal Contingencies
The company was subject to a Corporate Insolvency Resolution Process. A Resolution Plan was approved by the NCLT Mumbai Bench on July 31, 2025. A Monitoring Committee was established with its first meeting held on August 13, 2025, to oversee the implementation of the approved plan.
Risk Analysis
Key Uncertainties
The primary uncertainty is the successful implementation of the NCLT-approved Resolution Plan and the potential for further regulatory hurdles in the pharmaceutical sector impacting 76% of revenue.
Geographic Concentration Risk
80% of revenue is concentrated in the Indian domestic market, making the company vulnerable to local economic and regulatory shifts.
Third Party Dependencies
Dependency on distributors for sales in high-risk payment areas to mitigate credit risk.
Technology Obsolescence Risk
The company mitigates technology risk through its dedicated R&D center and focus on patented catalyst processes for niche molecules.
Credit & Counterparty Risk
The company manages credit exposure by shifting to shorter payment cycles (30 days) for new products and using distributors to handle collections from certain pharma clients.
